Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-NS-26-030
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing. This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may inclu...
Related opportunities
- Functional Target Validation for Alzheimer's Disease-Related DementiasNational Institutes of Health
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)National Institutes of Health
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)National Institutes of Health
- Exposomic Contributions to ADRD Pathology and ResilienceNational Institutes of Health
- Research Project Cooperative Agreements in Aging and/or Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) ResearchNational Institutes of Health
- Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)National Institutes of HealthCloses Nov 2027Up to $1.5M